Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis

In this report, we examined head-to-head the efficacy of a potent inhibitor of ATX (PF-8380), that has not been tested in pulmonary fibrosis models, and an antagonist of LPAR1 (AM095) in bleomycin (BLM)-induced pulmonary fibrosis. Both compounds abrogated the development of pulmonary fibrosis and prevented the distortion of lung architecture, exhibiting qualitative and quantitative differences in different manifestations of the modeled disease.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research